On 9 May 1960, the U.S. Food and Drug Administration authorised the first oral contraceptive for the prevention of pregnancy—an important milestone in reproductive medicine and public health.

The therapy, developed through the work of researchers including Dr Gregory Pincus and Dr John Rock, used synthetic hormones (oestrogen and a progestin) to suppress ovulation and reduce the likelihood of pregnancy.

Notably, the same medication had previously been authorised in 1957 for the treatment of certain menstrual disorders. The 1960 decision marked the first time a medicine was formally approved in the United States specifically for contraceptive use.

Why it mattered:

Medical impact: Introduced a reliable, non-invasive contraceptive option, supporting more consistent reproductive planning.

Innovation over time: Helped accelerate further research into hormone dosing, safety, and tolerability, leading to ongoing refinements in later decades.

Broader influence: Contributed to wider societal and policy discussions around family planning, reproductive autonomy, and participation in education and work.

The FDA’s 1960 approval is widely regarded as a defining moment—illustrating how advances in pharmaceuticals can shape both health outcomes and social change.